Equities research analysts at HC Wainwright raised their Q1 2025 earnings per share estimates for Sage Therapeutics in a ...

In a report released today, Joon Lee from Truist Financial maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report). The ...

Scotiabank analyst George Farmer maintained a Buy rating on SAGE Therapeutics (SAGE – Research Report) today and set a price target of $12.00.

Needham & Company LLC reiterated their hold rating on shares of Sage Therapeutics (NASDAQ:SAGE – Free Report) in a research report report published on Wednesday,Benzinga reports. Other equities ...

Sage Therapeutics (SAGE) delivered earnings and revenue surprises of -7.59% and 11.20%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

The 12-month price targets, analyzed by analysts, offer insights with an average target of $8.86, a high estimate of $14.00, ...

H.C. Wainwright analyst Douglas Tsao revised the price target for Sage Therapeutics (NASDAQ:SAGE) to $12.00 from the previous $14.00 while maintaining a Neutral rating on the company's shares. Tsao's ...

SAGE Therapeutics, Inc. (US) (SAGE) has disclosed a new risk, in the Litigation & Legal Liabilities category. SAGE Therapeutics, Inc. is currently ...

--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq ... including $2.3 million of non-cash stock-based compensation expense, in the fourth quarter of 2024 compared to $64.3 million, including ...

Sage Therapeutics stock gained after it announced that its board of directors has rejected the unsolicited, non-binding proposal offer from biotech giant Biogen to acquire the remaining shares of ...